Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2850922 | 0.99 | KDM1A (0.33) | KDM1ACYP17A1CYP11B1CYP11B2HTR2A | |
| SCHEMBL2846999 | 0.93 | KDM1A (0.31) | KDM1ACYP17A1CYP11B1CYP11B2 | |
| SCHEMBL2847709 | 0.90 | HTR2A (0.36) | KDM1AHTR2AHTR2CHTR2BCCR2 | |
| SCHEMBL2851468 | 0.89 | CTSC (0.31) | — | |
| SCHEMBL2854591 | 0.89 | KDM1A (0.33) | KDM1ACYP17A1CYP11B1CYP11B2HTR2A | |
| SCHEMBL2850888 | 0.88 | HTR2A (0.37) | KDM1AHTR2AHTR2CHTR2BCCR2 | |
| SCHEMBL11032393 | 0.88 | CYP17A1 (0.35) | KDM1ACYP17A1CYP11B1CYP11B2HTR2A | |
| SCHEMBL11032396 | 0.88 | CYP17A1 (0.35) | KDM1ACYP17A1CYP11B1CYP11B2HTR2A | |
| SCHEMBL2853591 | 0.85 | PTGS2 (0.36) | KDM1AHTR2AHTR2CHTR2B | |
| SCHEMBL8036615 | 0.83 | P2RY14 (0.33) | KDM1ACYP17A1CYP11B1CYP11B2P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100264368-A1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | TETRAGON-CHEMIE AG (LI) | 2010-10-21 | — | — | US | disclosed |
| EP-1896552-B1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | TETRAGON CHEMIE AG (LI) | 2010-05-19 | — | — | EP | disclosed |
| EP-1896552-A1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | Tetragon-Chemie AG (LI) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006136345-A1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | TETRAGON-CHEMIE AG (LI) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100264368-A1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | FLI1, F12, GTF2I | KDM1A 3877/4885CYP17A1 1785/4885CYP11B1 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.